Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
hepatocellular carcinoma | — | D006528 | C22.0 |
renal cell carcinoma | EFO_0000376 | D002292 | — |
thyroid neoplasms | EFO_0003841 | D013964 | — |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Liver neoplasms | D008113 | EFO_1001513 | C22.0 | 73 | 141 | 54 | 12 | 50 | 290 |
Hepatocellular carcinoma | D006528 | — | C22.0 | 56 | 104 | 46 | 10 | 38 | 222 |
Renal cell carcinoma | D002292 | EFO_0000376 | — | 12 | 41 | 16 | 1 | 29 | 92 |
Neoplasm metastasis | D009362 | EFO_0009708 | — | — | 3 | 1 | 1 | 1 | 5 |
Thrombosis | D013927 | — | — | 1 | 1 | — | 2 | — | 3 |
Hepatectomy | D006498 | — | — | — | — | — | 1 | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Neoplasms | D009369 | — | C80 | 54 | 17 | 5 | — | 7 | 78 |
Myeloid leukemia acute | D015470 | — | C92.0 | 21 | 17 | 4 | — | 8 | 41 |
Breast neoplasms | D001943 | EFO_0003869 | C50 | 9 | 21 | 1 | — | 2 | 28 |
Melanoma | D008545 | — | — | 7 | 15 | 2 | — | 2 | 24 |
Non-small-cell lung carcinoma | D002289 | — | — | 8 | 12 | 4 | — | 1 | 23 |
Kidney neoplasms | D007680 | EFO_0003865 | C64 | 7 | 6 | 3 | — | 6 | 21 |
Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 8 | 8 | 1 | — | — | 16 |
Thyroid neoplasms | D013964 | EFO_0003841 | — | — | 11 | 1 | — | 3 | 15 |
Leukemia | D007938 | — | C95 | 7 | 5 | 1 | — | 1 | 10 |
Adenocarcinoma | D000230 | — | — | — | 6 | 1 | — | — | 7 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Colorectal neoplasms | D015179 | — | — | 5 | 10 | — | — | 3 | 16 |
Lung neoplasms | D008175 | HP_0100526 | C34.90 | 6 | 9 | — | — | 1 | 15 |
Prostatic neoplasms | D011471 | — | C61 | 6 | 10 | — | — | — | 14 |
Sarcoma | D012509 | — | — | 5 | 10 | — | — | — | 13 |
Glioblastoma | D005909 | EFO_0000515 | — | 7 | 8 | — | — | — | 12 |
Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | 7 | 3 | — | — | 1 | 10 |
Urinary bladder neoplasms | D001749 | — | C67 | 2 | 7 | — | — | — | 9 |
Myelodysplastic syndromes | D009190 | — | D46 | 6 | 5 | — | — | — | 9 |
Brain neoplasms | D001932 | EFO_0003833 | C71 | 6 | 3 | — | — | 1 | 8 |
Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 1 | 8 | — | — | — | 8 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Megakaryoblastic leukemia acute | D007947 | — | C94.2 | 3 | — | — | — | — | 3 |
Myelomonocytic leukemia acute | D015479 | — | C92.5 | 3 | — | — | — | — | 3 |
Basophilic leukemia acute | D015471 | — | C94.8 | 3 | — | — | — | — | 3 |
Erythroblastic leukemia acute | D004915 | EFO_1001257 | C94.0 | 3 | — | — | — | — | 3 |
Eosinophilic leukemia acute | D015472 | — | — | 3 | — | — | — | — | 3 |
Non-hodgkin lymphoma | D008228 | — | C85.9 | 2 | — | — | — | — | 2 |
Astrocytoma | D001254 | EFO_0000271 | — | 2 | — | — | — | — | 2 |
Oligodendroglioma | D009837 | EFO_0000631 | — | 2 | — | — | — | — | 2 |
Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | 1 | — | — | — | 1 | 2 |
Myeloid leukemia | D007951 | — | C92 | 2 | — | — | — | — | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Drug-related side effects and adverse reactions | D064420 | — | T88.7 | — | — | — | — | 1 | 1 |
Hypertension | D006973 | EFO_0000537 | I10 | — | — | — | — | 1 | 1 |
Proteinuria | D011507 | HP_0000093 | R80 | — | — | — | — | 1 | 1 |
Gastrointestinal neoplasms | D005770 | — | C26.9 | — | — | — | — | 1 | 1 |
Progression-free survival | D000077982 | — | — | — | — | — | — | 1 | 1 |
Radiofrequency ablation | D000078703 | — | — | — | — | — | — | 1 | 1 |
Apoptosis | D017209 | — | — | — | — | — | — | 1 | 1 |
Covid-19 | D000086382 | — | U07.1 | — | — | — | — | 1 | 1 |
Infections | D007239 | EFO_0000544 | — | — | — | — | — | 1 | 1 |
Sarcopenia | D055948 | EFO_1000653 | M62.84 | — | — | — | — | 1 | 1 |
Drug common name | Sorafenib |
INN | sorafenib |
Description | Sorafenib is a member of the class of phenylureas that is urea in which one of the nitrogens is substituted by a 4-chloro-3-trifluorophenyl group while the other is substituted by a phenyl group which, in turn, is substituted at the para position by a [2-(methylcarbamoyl)pyridin-4-yl]oxy group. It has a role as an antineoplastic agent, an EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor, a tyrosine kinase inhibitor, an angiogenesis inhibitor, an anticoronaviral agent and a ferroptosis inducer. It is a pyridinecarboxamide, a member of monochlorobenzenes, an aromatic ether, a member of (trifluoromethyl)benzenes and a member of phenylureas. |
Classification | Small molecule |
Drug class | rapidly accelerated fibrosarcoma (RAF) kinase inhibitors |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1 |
PDB | — |
CAS-ID | 284461-73-0 |
RxCUI | — |
ChEMBL ID | CHEMBL1336 |
ChEBI ID | 50924 |
PubChem CID | 216239 |
DrugBank | DB00398 |
UNII ID | 9ZOQ3TZI87 (ChemIDplus, GSRS) |